 [1m([0morchestrator-myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes DESIPRAMINE increase or decrease the risk of myocardial [0m
[34minfarction?[0m
 [1m([0morchestrator-myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-DESIPRAMINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does DESIPRAMINE increase or decrease the risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-DESIPRAMINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes DESIPRAMINE increase or decrease the risk of myocardial [0m
[32minfarction?[0m
 [1m([0morchestrator-myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes DESIPRAMINE increase or decrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does DESIPRAMINE increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"DESIPRAMINE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: DESIPRAMINE: contraindications: CONTRAINDICATIONS The use of MAOIs intended to treat psychiatric disorders with desipramine hydrochloride or within [0m[1;31m14[0m[31m days of stopping treatment with [0m
[31mdesipramine hydrochloride is contraindicated because of an increased risk of serotonin syndrome. The use of desipramine hydrochloride within [0m[1;31m14[0m[31m days of stopping an MAOI intended to treat psychiatric [0m
[31mdisorders is also contraindicated [0m[1;31m([0m[31m see WARNINGS and DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Starting desipramine hydrochloride in a patient who is being treated with MAOIs such as linezolid or intravenous [0m
[31mmethylene blue is also contraindicated because of an increased risk of serotonin syndrome [0m[1;31m([0m[31msee WARNINGS and DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Desipramine hydrochloride is contraindicated in the acute [0m
[31mrecovery period following myocardial infarction. It should not be used in those who have shown prior hypersensitivity to the drug. DESIPRAMINE: contraindications: Cross-sensitivity between this and [0m
[31mother dibenzazepines is a possibility.         [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mSIPRAMINE label[0m


[31mCONTENT: DESIPRAMINE: boxed_warning: Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior [0m[1;31m([0m[31msuicidality[0m[1;31m)[0m[31m in children, [0m
[31madolescents, and young adults in short-term studies of major depressive disorder [0m[1;31m([0m[31mMDD[0m[1;31m)[0m[31m and other psychiatric disorders. Anyone considering the use of desipramine hydrochloride tablets or any other [0m
[31mantidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants [0m
[31mcompared to placebo in adults beyond age [0m[1;31m24[0m[31m; there was a reduction in risk with antidepressants compared to placebo in adults aged [0m[1;31m65[0m[31m and older. Depression and certain other psychiatric disorders are [0m
[31mthemselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical [0m
[31mworsening, suicidality, or unusual changes in behavior. DESIPRAMINE: boxed_warning: Families and caregivers should be advised of the need for close observation and communication with the prescriber. [0m
[31mDesipramine hydrochloride is not approved for use in pediatric patients [0m[1;31m([0m[31m See WARNINGS: Clinical Worsening and Suicide Risk , PRECAUTIONS: Information for Patients , and PRECAUTIONS: Pediatric Use .  [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mSIPRAMINE label[0m


[31mCONTENT: DESIPRAMINE: warnings: Screening Patients for Bipolar Disorder: A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed [0m[1;31m([0m[31mthough not [0m
[31mestablished in controlled trials[0m[1;31m)[0m[31m that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar [0m
[31mdisorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be[0m
[31madequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and [0m
[31mdepression. It should be noted that desipramine hydrochloride is not approved for use in treating bipolar depression. DESIPRAMINE: warnings: Serotonin Syndrome: The development of a potentially [0m
[31mlife-threatening serotonin syndrome has been reported with serotonin norepinephrine reuptake inhibitors [0m[1;31m([0m[31mSNRIs[0m[1;31m)[0m[31m and SSRIs, including desipramine hydrochloride, alone but particularly with concomitant [0m
[31muse of other serotonergic drugs [0m[1;31m([0m[31mincluding triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort[0m[1;31m)[0m[31m and with drugs that impair metabolism of [0m
[31mserotonin [0m[1;31m([0m[31min particular, MAOIs both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue[0m[1;31m)[0m[31m. Serotonin syndrome symptoms may include mental [0m
[31mstatus changes [0m[1;31m([0m[31me.g., agitation, hallucinations, delirium, and coma[0m[1;31m)[0m[31m, autonomic instability [0m[1;31m([0m[31me.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia[0m[1;31m)[0m[31m, neuromuscular [0m
[31mchanges [0m[1;31m([0m[31me.g. DESIPRAMINE: warnings: tremor, rigidity, myoclonus, hyperreflexia, incoordination[0m[1;31m)[0m[31m, seizures, and/or gastrointestinal symptoms [0m[1;31m([0m[31me.g., nausea, vomiting, diarrhea[0m[1;31m)[0m[31m. Patients should be [0m
[31mmonitored for the emergence of serotonin syndrome. The concomitant use of desipramine hydrochloride with MAOIs intended to treat psychiatric disorders is contraindicated. Desipramine hydrochloride [0m
[31mshould also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of [0m
[31madministration involved intravenous administration in the dose range of [0m[1;31m1[0m[31m mg/kg to [0m[1;31m8[0m[31m mg/kg. No reports involved the administration of methylene blue by other routes [0m[1;31m([0m[31msuch as oral tablets or local [0m
[31mtissue injection[0m[1;31m)[0m[31m or at lower doses. DESIPRAMINE: warnings: There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a [0m
[31mpatient taking desipramine hydrochloride. Desipramine hydrochloride should be discontinued before initiating treatment with the MAOI [0m[1;31m([0m[31m see CONTRAINDICATIONS and DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. If [0m
[31mconcomitant use of desipramine hydrochloride with other serotonergic drugs including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John's Wort is [0m
[31mclinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome particularly during treatment initiation and dose increases. Treatment with desipramine [0m
[31mhydrochloride and any concomitant serotonergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated. DESIPRAMINE: warnings: [0m
[31mAngle-Closure Glaucoma: The pupillary dilation that occurs following use of many antidepressant drugs including desipramine hydrochloride may trigger an angle closure attack in a patient with [0m
[31manatomically narrow angles who does not have a patent iridectomy. General Extreme caution should be used when this drug is given in the following situations: In patients with cardiovascular disease, [0m
[31mbecause of the possibility of conduction defects, arrhythmias, tachycardias, strokes, and acute myocardial infarction. In patients who have a family history of sudden death, cardiac dysrhythmias, or [0m
[31mcardiac conduction disturbances. In patients with a history of urinary retention or glaucoma, because of the anticholinergic properties of the drug. In patients with thyroid disease or those taking [0m
[31mthyroid medication, because of the possibility of cardiovascular toxicity, including arrhythmias. In patients with a history of seizure disorder, because this drug has been shown to lower the seizure [0m
[31mthreshold. DESIPRAMINE: warnings: Seizures precede cardiac dysrhythmias and death in some patients. This drug is capable of blocking the antihypertensive effect of guanethidine and similarly acting [0m
[31mcompounds. The patient should be cautioned that this drug may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating[0m
[31mmachinery. In patients who may use alcohol excessively, it should be borne in mind that the potentiation may increase the danger inherent in any suicide attempt or overdosage. Pregnancy There is a [0m
[31mpregnancy exposure registry that monitors pregnancy outcomes in woman exposed to antidepressants, including desipramine hydrochloride tablets during pregnancy. Healthcare providers are encouraged to [0m
[31mregister patients by calling the National Pregnancy Registry for Antidepressants at [0m[1;31m1[0m[31m-[0m[1;31m844[0m[31m-[0m[1;31m405[0m[31m-[0m[1;31m6185[0m[31m or visiting online at [0m[4;31mhttp://womensmentalhealth.[0m[31m DESIPRAMINE: warnings: [0m[31m/[0m[31mclinical-and-research-[0m[31m [0m
[31mprograms/pregnancyregistry/antidepressants Safe use of desipramine hydrochloride during pregnancy and lactation has not been established; therefore, if it is to be given to pregnant patients, nursing [0m
[31mmothers, or women of childbearing potential, the possible benefits must be weighed against the possible hazards to mother and child. Animal reproductive studies have been inconclusive. Geriatric Use [0m
[31mClinical studies of desipramine hydrochloride did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and over to determine whether they respond differently from younger subjects. Other reported [0m
[31mclinical experience has not identified differences in responses between the elderly and younger patients. Lower doses are recommended for elderly patients. [0m[1;31m([0m[31m See DOSAGE AND ADMINISTRATION .[0m[1;31m)[0m[31m The ratio[0m
[31mof [0m[1;31m2[0m[31m-hydroxydesipramine to desipramine may be increased in the elderly, most likely due to decreased renal elimination with aging. DESIPRAMINE: warnings: This drug is known to be substantially [0m
[31mexcreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function,[0m
[31mcare should be taken in dose selection, and it may be useful to monitor renal function. Desipramine hydrochloride use in the elderly has been associated with a proneness to falling as well as [0m
[31mconfusional states [0m[1;31m([0m[31mSee ADVERSE REACTIONS .         [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mSIPRAMINE label[0m


[31mCONTENT: DESIPRAMINE: adverse_reactions: ADVERSE REACTIONS Included in the following listing are a few adverse reactions that have not been reported with this specific drug. However, the pharmacologic[0m
[31msimilarities among the tricyclic antidepressant drugs require that each of the reactions be considered when desipramine hydrochloride is given. Cardiovascular: Hypotension, hypertension, palpitations,[0m
[31mheart block, myocardial infarction, stroke, arrhythmias, premature ventricular contractions, tachycardia, ventricular tachycardia, ventricular fibrillation, sudden death There has been a report of an [0m
[31m"acute collapse"[0m[31m and [0m[31m"sudden death"[0m[31m in an [0m[1;31m8[0m[31m-year-old [0m[1;31m([0m[1;31m18[0m[31m kg[0m[1;31m)[0m[31m male, treated for [0m[1;31m2[0m[31m years for hyperactivity. DESIPRAMINE: adverse_reactions: There have been additional reports of sudden death in children[0m
[1;31m([0m[31m See PRECAUTIONS- Pediatric Use [0m[1;31m)[0m[31m Psychiatric: Confusional states [0m[1;31m([0m[31mespecially in the elderly[0m[1;31m)[0m[31m with hallucinations, disorientation, delusions; anxiety, restlessness, agitation; insomnia and [0m
[31mnightmares; hypomania; exacerbation of psychosis Neurologic: Numbness, tingling, paresthesias of extremities; incoordination, ataxia, tremors; peripheral neuropathy; extrapyramidal symptoms; seizures;[0m
[31malterations in EEG patterns; tinnitus . Symptoms attributed to Neuroleptic Malignant Syndrome have been reported during desipramine use with and without concomitant neuroleptic therapy. DESIPRAMINE: [0m
[31madverse_reactions: Anticholinergic: Dry mouth, and rarely associated sublingual adenitis; blurred vision, disturbance of accommodation, mydriasis, increased intraocular pressure; constipation, [0m
[31mparalytic ileus; urinary retention, delayed micturition, dilation of urinary tract Allergic: Skin rash, petechiae, urticaria, itching, photosensitization [0m[1;31m([0m[31mavoid excessive exposure to sunlight[0m[1;31m)[0m[31m, edema [0m
[1;31m([0m[31mof face and tongue or general[0m[1;31m)[0m[31m, drug fever, cross- sensitivity with other tricyclic drugs Hematologic: Bone marrow depressions including agranulocytosis, eosinophilia, purpura, thrombocytopenia [0m
[31mGastrointestinal: Anorexia, nausea and vomiting, epigastric distress, peculiar taste, abdominal cramps, diarrhea, stomatitis, black tongue, hepatitis, jaundice [0m[1;31m([0m[31msimulating obstructive[0m[1;31m)[0m[31m, altered liver [0m
[31mfunction, elevated liver function tests, increased pancreatic enzymes Endocrine: Gynecomastia DESIPRAMINE: adverse_reactions: in the male, breast enlargement and galactorrhea in the female; increased [0m
[31mor decreased libido, impotence, painful ejaculation, testicular swelling; elevation or depression of blood sugar levels; syndrome of inappropriate antidiuretic hormone secretion [0m[1;31m([0m[31mSIADH[0m[1;31m)[0m[31m Other: Weight [0m
[31mgain or loss; perspiration, flushing; urinary frequency, nocturia; parotid swelling; drowsiness, dizziness, proneness to falling, weakness and fatigue, headache; fever; alopecia; elevated alkaline [0m
[31mphosphatase Withdrawal Symptoms: Though not indicative of addiction, abrupt cessation of treatment after prolonged therapy may produce nausea, headache, and malaise. To report SUSPECTED ADVERSE [0m
[31mREACTIONS, contact Chartwell RX, LLC. at [0m[1;31m1[0m[31m-[0m[1;31m845[0m[31m-[0m[1;31m232[0m[31m-[0m[1;31m1683[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www.fda.gov/medwatch.         [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mSIPRAMINE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Desipramine is contraindicated in the acute recovery period following myocardial infarction, indicating that there is an increased risk associated with its use in this context. Additionally, [0m
[32mextreme caution is advised when desipramine is given to patients with cardiovascular disease due to the possibility of conduction defects, arrhythmias, tachycardias, strokes, and acute myocardial [0m
[32minfarction.[0m

[32mSOURCE: DESIPRAMINE label[0m
[32mEXTRACT_START_END: Desipramine hydrochloride is contraindicated[0m[32m...[0m[32m following myocardial infarction. [0m[32m/[0m[32m [0m[32m...[0m[32mpossibility of conduction defects, arrhythmias, tachycardias, strokes, and acute myocardial [0m
[32minfarction.[0m
*[1m([0morchestrator-myocardial infarction-DESIPRAMINE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Desipramine is contraindicated in the acute recovery [0m
[34mperiod following myocardial infarction, indicating that there is an increased risk associated with its use in this context. Additionally, extreme caution is advised when desipramine is given to [0m
[34mpatients with cardiovascular disease due to the possibility of conduction defects, arrhythmias, tachycardias, strokes, and acute myocardial infarction.[0m

[34mSOURCE: DESIPRAMINE label[0m
[34mEXTRACT_START_END: Desipramine hydrochloride is contraindicated[0m[34m...[0m[34m following myocardial infarction. [0m[34m/[0m[34m [0m[34m...[0m[34mpossibility of conduction defects, arrhythmias, tachycardias, strokes, and acute myocardial [0m
[34minfarction.[0m
 [1m([0morchestrator-myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-DESIPRAMINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does DESIPRAMINE increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if DESIPRAMINE increases or decreases the risk of myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that DESIPRAMINE is contraindicated in the acute recovery period following myocardial infarction, indicating an increased risk associated with its use in this context. [0m
[32mAdditionally, extreme caution is advised when DESIPRAMINE is given to patients with cardiovascular disease due to the possibility of conduction defects, arrhythmias, tachycardias, strokes, and acute [0m
[32mmyocardial infarction."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DESIPRAMINE is associated with an increased risk of myocardial infarction, especially in patients in the acute recovery period following a myocardial infarction or those with [0m
[32mcardiovascular disease."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-DESIPRAMINE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-myocardial infarction-DESIPRAMINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does DESIPRAMINE increase or decrease the risk of myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if DESIPRAMINE increases or decreases the risk of myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that DESIPRAMINE is contraindicated in the acute recovery period following myocardial infarction, indicating an increased risk associated with its use in this context. [0m
[34mAdditionally, extreme caution is advised when DESIPRAMINE is given to patients with cardiovascular disease due to the possibility of conduction defects, arrhythmias, tachycardias, strokes, and acute [0m
[34mmyocardial infarction."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DESIPRAMINE is associated with an increased risk of myocardial infarction, especially in patients in the acute recovery period following a myocardial infarction or those with [0m
[34mcardiovascular disease."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does DESIPRAMINE increase or decrease the risk of myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if DESIPRAMINE increases or decreases the risk of myocardial infarction.[0m
[1;31m2[0m[31m. FDAHandler responded that DESIPRAMINE is contraindicated in the acute recovery period following myocardial infarction, indicating an increased risk associated with its use in this context. [0m
[31mAdditionally, extreme caution is advised when DESIPRAMINE is given to patients with cardiovascular disease due to the possibility of conduction defects, arrhythmias, tachycardias, strokes, and acute [0m
[31mmyocardial infarction.[0m
[31m        -----[0m
[31m        Final answer: DESIPRAMINE is associated with an increased risk of myocardial infarction, especially in patients in the acute recovery period following a myocardial infarction or those with [0m
[31mcardiovascular disease.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided seems to be consistent with medical knowledge and common sense. The user has correctly inferred from the contraindication and cautionary advice regarding [0m
[32mDESIPRAMINE in patients with cardiovascular issues that there is an increased risk of myocardial infarction associated with its use. The user has also appropriately relied on the response from [0m
[32mFDAHandler to draw this conclusion. There are no apparent flaws in the reasoning process."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-myocardial infarction-DESIPRAMINE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided seems to be consistent with medical knowledge and common sense. The user has correctly inferred from the contraindication and cautionary advice regarding [0m
[34mDESIPRAMINE in patients with cardiovascular issues that there is an increased risk of myocardial infarction associated with its use. The user has also appropriately relied on the response from [0m
[34mFDAHandler to draw this conclusion. There are no apparent flaws in the reasoning process."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-myocardial infarction-DESIPRAMINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided seems to be consistent with medical knowledge and common sense. The user has correctly inferred from the contraindication and cautionary advice regarding [0m
[31mDESIPRAMINE in patients with cardiovascular issues that there is an increased risk of myocardial infarction associated with its use. The user has also appropriately relied on the response from [0m
[31mFDAHandler to draw this conclusion. There are no apparent flaws in the reasoning process.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0morchestrator-myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-DESIPRAMINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mDESIPRAMINE is associated with an increased risk of myocardial infarction, especially in patients in the acute recovery period following a myocardial infarction or those with cardiovascular disease. [0m
[32mThis is based on the information provided by FDAHandler, which indicates that DESIPRAMINE is contraindicated in the acute recovery period following myocardial infarction and that extreme caution is [0m
[32madvised when it is given to patients with cardiovascular disease due to the possibility of conduction defects, arrhythmias, tachycardias, strokes, and acute myocardial infarction.[0m
